Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 141 for “"PD-1"”.
-
PD-1 AND PD-1 LIGAND REGULATION OF NATURAL ANTIBODY SPECIFICITIES AND THE ADAPTIVE RESPONSE TO PNEUMOCOCCAL POLYSACCHARIDES
… the past three decades. Programmed cell death-1 (PD-1) is a surface-expressed receptor of the B7/CD28 superfamily and the subject of considerable study since its discovery in 1992 [1]. The available literature lacks an in-depth understanding of the role of PD-1 and PD-1 ligands (PD-L) in B cell …
-
The Role of the PD-1 Immunoreceptor in Pregnancy
… We propose that the CD28 family immune receptor, PD-1, functions during pregnancy to control maternal immune reactions. PD-1 is expressed on T lymphocytes and following interaction with its ligand, B7-H1, prevents T cell activation. B7-H1 is expressed in the human placenta throughout gestation, …
-
Micrornas Associated With Melanoma Inflammation and Response to Pd-1 Inhibition
… investigation of these microRNAs in a cohort of PD-1 inhibitor treated melanoma patients identified a survival benefit in patients whose melanomas had high expression of miR-100-5p and miR-125b-5p. These findings indicate that microRNA regulation of gene expression in melanoma is relevant to …
-
Loss of Ptdss1 in tumor cells improves anti-PD-1 therapy
… we identified PTDSS1 as a target to improve anti-PD-1 therapy. Depletion of PTDSS1 in tumor cells increased expression of IFNγ-regulated genes, including B2m, Cxcl9, Cxcl10, and Stat1. Loss of PTDSS1 in tumor cells also led to increased expression of MHC-I, which was associated with increased …
-
The role of the PD-1 pathway in the tumor microenvironment
… antibodies blocking the programmed death (PD)-1 pathway have been approved for the treatment of metastatic melanoma, non-small cell lung cancer, and renal cell carcinoma, amongst others. However, only a limited number of patients respond to these therapies. The field is now trying to …
-
An Affinity Threshold for Maximum Efficacy in Anti-PD-1 Cancer Immunotherapy
… targeted to the programmed cell death protein 1 (PD-1) remain the most prevalent cancer immunotherapy both as a monotherapy and in combination with additional therapies. Despite the extensive success of anti-PD-1 mAbs in the clinic, the experimental relationship between binding affinity and …
-
Targeting Pd-1/Pdl-1 Signaling In The Treatment of Osteosarcoma Lung Metastasis
… such as binding of immune inhibitory receptor, PD-1 with PDL-1, which is upregulated in cancer cells, may cause disease relapse.</p> <p>The effect of PD-1 blockade on NK cells and macrophages has not been investigated till date. The aim of this study was to determine if PD-1 blockade leads to of …
-
Regulation of Anti-Viral Cd8+ T Cell Responses by the Pd-1 Pathway
PD-1 and its ligands, PD-L1 and PD-L2, constitute a critical immunoregulatory pathway for modulating CD8+ T cell responses. This pathway has become an important therapeutic target in cancer and chronic viral infections, where blockade of PD-1/PD-L1 reverses CD8+ T cell exhaustion and improves …
-
T-cell Dysfunction by HCV Core Protein Involves PD-1/PD-L1 Signaling.
… of a negative co-stimulatory pathway mediated by PD-1 and PDL-1 is associated with persistent viral infection. The role, if any, that PD-1/PDL-1 has in HCV infection is unknown. In this study we report that PD-1 is upregulated in T-cells from persons with chronic HCV infection when compared to …
-
Assessing Tumor Mutation Burden and Correlation With Anti-PD-1/L1 Therapy Benefit and Prognosis
The general metadata -- e.g., title, author, abstract, subject headings, etc. -- is publicly available, but access to the submitted files is restricted to UT Southwestern campus access and/or authorized UT Southwestern users.
-
IMPAIRMENT OF TOLL-LIKE RECEPTOR 9 AGONIST ANTI-TUMOR ACTIVITY BY ANTI-PD-1 ANTIBODY: ROLE OF MACROPHAGES
… un aumento dell’espressione del recettore PD-1 sulle cellule immuni. PD-1 è espresso dalle cellule del sistema immunitario sia innato sia adattativo e, in seguito al legame con i suoi due ligandi (PD-L1 e –L2), provoca lo spegnimento dell’attività del sistema immunitario. Per sfuggire …
-
Study of Regulated Cell Death In Two Systems: Pd-1 In Natural Killer Cells and Rip3 In Neurons
… molecules involved in RCD: programmed death 1 (PD-1, as inhibitor for RCD) and serine/threonine kinase receptor interaction protein 3 (RIP3, as promoter for RCD) in two different systems.</p> <p>First, I studied the role of PD-1 signaling in the cytotoxicity of natural killer (NK) cells. In …
-
AXL Targeting Restores PD-1 Blockade Sensitivity of STK11/LKB1 Mutant NSCLC Through Expansion of TCF1+ CD8 T Cells
… cells that expands tumor-associated TCF1+ PD-1+ CD8 T cells, restoring therapeutic response to PD-1 ICB for KPL tumors. This effect was observed in syngeneic immunocompetent mouse models and in humanized mice bearing STK11/LKB1 mutant NSCLC human tumor xenografts. Anecdotal NSCLC patients …
-
Novel Imaging-Based Techniques Reveal A Role For Pd-1/Pd-L1 In Tumor Immune Surveillance In The Lung
… immune inhibitory receptor Programmed Death 1 (PD-1) on T cells to its ligand PD-L1 has been implicated as a major contributor to tumor induced immune suppression. Clinical trials of PD-L1 blockade have proven effective in unleashing therapeutic anti-tumor immune responses in a subset of …
-
The Cx3Cl1-Cx3Cr1 Chemokine Axis Contributes to Tumor Immune Evasion and Its Blockade Enhances Responses to Anti-Pd-1 Immunotherapy
… the underlying mechanisms of resistance to anti-PD-1 immunotherapy. We used a novel monoclonal antibody against mouse CX3CR1 that binds to CX3CR1, blocks the CX3CL1-CX3CR1 interaction and antagonizes the pro-tumorigenic outcome of this axis. This monoclonal antibody reduces migration of tumor …
-
Tumour Associated Neutrophils as a Potential Biomarker for Anti-PD-1 Immunotherapy in Non-Small Cell Lung Carcinoma: An Automated Approach
Background: Despite recent advancements in immunotherapy and clinical biomarkers for the treatment of lung adenocarcinoma (LUAD), objective response rates are still low at around 20%. Current biomarkers are limited in their ability to stratify patients for predicting response, highlighting the need …
-
Integrative Cancer Immunogenomic Analysis of Serial Melanoma Biopsies Reveals Correlates of Response and Resistance to Sequential Ctla-4 and Pd-1 Blockade Treatment
… followed by programmed death receptor–1 (PD-1) by immunogenomic profile analyses from serial tumor biopsies.</p> <p>From immune profiling (12 marker immunohistochemistry and NanoString Gene Expression Profiling), we found that adaptive immune signatures in tumor biopsies obtained from …
Page 1 of 8